In a filing, Autolus Therapeutics plc ADR revealed its Officer Martin Pule acquired Company’s shares for reported $2.96 million on Sep 16 ’24. In the deal valued at $4.23 per share,698,741 shares were bought.
Goldman upgraded its Autolus Therapeutics plc ADR [AUTL] rating to a Buy from a a Neutral in a research note published on November 18, 2024; the price target was increased to $7.60 from $7. A number of analysts have revised their coverage, including Redburn Atlantic’s analysts, who increased its forecast for the stock in mid November from “a Neutral” to “a Buy”. Deutsche Bank began covering AUTL with “Buy” recommendation on November 09, 2023.
Price Performance Review of AUTL
On Monday, Autolus Therapeutics plc ADR [NASDAQ:AUTL] saw its stock fall -1.48% to $1.33. Over the last five days, the stock has lost -4.32%. Autolus Therapeutics plc ADR shares have fallen nearly -43.40% since the year began. Nevertheless, the stocks have fallen -66.75% over the past one year. While a 52-week high of $5.00 was reached on 01/03/25, a 52-week low of $1.11 was recorded on 04/11/25. SMA at 50 days reached $1.6003, while 200 days put it at $2.8964.
Levels Of Support And Resistance For AUTL Stock
The 24-hour chart illustrates a support level at 1.2969, which if violated will result in even more drops to 1.2638. On the upside, there is a resistance level at 1.3662. A further resistance level may holdings at 1.4024. The Relative Strength Index (RSI) on the 14-day chart is 43.51, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0567, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.67%. Stochastics %K at 23.65% indicates the stock is a holding.
The most recent change occurred on March 17, 2023 when Bryan Garnier began covering the stock and recommended ‘”a Buy”‘ rating along with a $5 price target.
